[Persistent hyperinsulinemic hypoglycemia of infancy: the pathologist's experience]

Christine Sempoux1, Yves Guiot, Henri Noël

  • 1Département d'Anatomie Pathologique, Cliniques Universitaires Saint Luc, 10, avenue Hippocrate, 1200 Bruxelles, Belgique, France. rahier@anps.ucl.ac.be

Annales De Pathologie
|December 17, 2002
PubMed

Insights

Persistent hyperinsulinemic hypoglycemia of Infancy (PHHI) is a condition causing severe low blood sugar. Research suggests an intrinsic functional defect in pancreatic beta cells, not just cell mass changes, underlies diffuse PHHI.

Area of Science:

  • Endocrinology
  • Pediatric Pathology
  • Surgical Pathology

Context:

  • Persistent hyperinsulinemic hypoglycemia of Infancy (PHHI) presents significant neurological risks due to severe hypoglycemia.
  • PHHI exhibits focal or diffuse pancreatic anomalies, with diffuse forms often appearing normal and requiring extensive surgery.

Purpose:

  • To investigate pathogenic hypotheses for the diffuse form of PHHI.
  • To evaluate the roles of nesidioblastosis, beta cell mass, delta cell mass, and intrinsic beta cell function.

Summary:

  • Nesidioblastosis is present but not specific or indicative of proliferation.
  • Increased beta cell mass is not consistently observed.
  • Decreased delta cell mass is inconsistent.
  • Evidence supports intrinsic beta cell functional lesions, including increased proinsulin in the Golgi and morphological changes in beta cells.

Impact:

  • Findings guide surgical treatment for diffuse PHHI by identifying histological anomalies on frozen sections.
  • Clarifies the pathophysiology of diffuse PHHI, moving beyond simple cell mass alterations.
  • Improves understanding of a rare but serious infant condition.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...